Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Market Barriers to the Development of COCAINE Pharmacotherapies

09/12/1997

The purpose of this section is to characterize private industry's views on market barriers to anti-addiction pharmacotherapy development. The 1995 IOM report, Development of Medications for the Treatment of Opiate and Cocaine Addictions, identified numerous market obstacles that appear to hamper private sector investment in anti-addiction medication development, e.g., market size, development costs, regulatory requirements for approval, and social attitudes about drug abuse (see Figure 35). This section pulls together industry views on these and other market barriers to pharmacotherapies for cocaine abuse and addiction with the objective of identifying barriers with the greatest impact on industry investment decisions. Additional information gathered for this section provides insights into estimating the relative import of various market barriers, including those considered to be "make-or-break" or otherwise critical barriers, and of the feasibility of surmounting them under current circumstances.


Figure 35: Market Obstacles & Creating Incentive

Figure 35: Market Obstacles & Creating Incentive

Source: IOM, Development of Medications for the Treatment of Opiate and Cocaine Addictions, 1995.


This section contains information from four sources: a) interviews with executives from five private firms (three pharmaceutical and two venture capital firms); b) the market analysis for a prospective cocaine medication; and c) scenarios of company decisionmaking; and d) case study reports of LAAM, naltrexone, clozapine, and Nicorette. The case study reports, market analysis, and scenarios of company decisionmaking provide information about the market potential for cocaine medications and lessons on development and marketing from previously developed pharmacotherapies.

The interviews with executives of private firms helped to identify the barriers to industry development of medications for cocaine abuse and addiction. It is important to note that the small sample of firms precludes either a representative study or assurance that all possible barriers have been identified. Instead, the primary goal of the interviews with the executives of private firms was to better understand the relative significance of barriers to this market.